PerkinElmer, Inc. (PKI) Director Sells $365,900.00 in Stock

PerkinElmer, Inc. (NYSE:PKI) Director Alexis P. Michas sold 5,000 shares of PerkinElmer stock in a transaction dated Thursday, November 30th. The stock was sold at an average price of $73.18, for a total value of $365,900.00. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Shares of PerkinElmer, Inc. (NYSE:PKI) traded down $0.56 on Friday, hitting $73.12. The stock had a trading volume of 467,175 shares, compared to its average volume of 631,420. The company has a debt-to-equity ratio of 0.44, a quick ratio of 2.09 and a current ratio of 2.59. PerkinElmer, Inc. has a 12-month low of $50.51 and a 12-month high of $74.11. The company has a market cap of $8,060.00, a PE ratio of 26.55, a P/E/G ratio of 2.21 and a beta of 0.77.

The business also recently declared a quarterly dividend, which will be paid on Friday, February 9th. Stockholders of record on Friday, January 19th will be given a $0.07 dividend. The ex-dividend date of this dividend is Thursday, January 18th. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.38%. PerkinElmer’s dividend payout ratio is currently 12.67%.

Several brokerages have issued reports on PKI. Piper Jaffray Companies reaffirmed a “buy” rating and set a $81.00 price target on shares of PerkinElmer in a research note on Friday, August 4th. Citigroup reiterated a “buy” rating and issued a $80.00 price objective (up previously from $74.00) on shares of PerkinElmer in a report on Tuesday, September 26th. Cowen reiterated a “hold” rating and issued a $70.00 price objective on shares of PerkinElmer in a report on Friday, September 1st. Robert W. Baird reiterated a “buy” rating and issued a $72.00 price objective on shares of PerkinElmer in a report on Friday, October 20th. Finally, Morgan Stanley reiterated an “overweight” rating and issued a $77.00 price objective (down previously from $79.00) on shares of PerkinElmer in a report on Friday, October 6th. Two analysts have rated the stock with a sell rating, nine have given a hold rating and six have given a buy rating to the company’s stock. PerkinElmer currently has a consensus rating of “Hold” and a consensus price target of $68.64.

A number of hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its position in PerkinElmer by 2.6% in the 2nd quarter. Vanguard Group Inc. now owns 10,886,642 shares of the medical research company’s stock valued at $741,816,000 after acquiring an additional 273,975 shares in the last quarter. Janus Henderson Group PLC bought a new position in PerkinElmer in the 2nd quarter valued at approximately $436,483,000. BlackRock Inc. lifted its position in PerkinElmer by 2.4% in the 2nd quarter. BlackRock Inc. now owns 5,929,277 shares of the medical research company’s stock valued at $404,022,000 after acquiring an additional 141,650 shares in the last quarter. Pictet Asset Management Ltd. lifted its position in PerkinElmer by 2.1% in the 2nd quarter. Pictet Asset Management Ltd. now owns 3,433,659 shares of the medical research company’s stock valued at $216,526,000 after acquiring an additional 71,540 shares in the last quarter. Finally, King Luther Capital Management Corp lifted its position in PerkinElmer by 1.3% in the 3rd quarter. King Luther Capital Management Corp now owns 2,562,833 shares of the medical research company’s stock valued at $176,759,000 after acquiring an additional 32,248 shares in the last quarter. 91.66% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This article was first reported by American Banking News and is owned by of American Banking News. If you are reading this article on another site, it was illegally stolen and reposted in violation of U.S. and international copyright legislation. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/12/01/perkinelmer-inc-pki-director-sells-365900-00-in-stock.html.

PerkinElmer Company Profile

PerkinElmer, Inc is a provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment serves the environmental, food, industrial, life sciences research and laboratory services markets.

Insider Buying and Selling by Quarter for PerkinElmer (NYSE:PKI)

Receive News & Ratings for PerkinElmer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply